Advertisement
BMRN vs INCY
Which Stock Would AI Choose? BioMarin Pharmaceutical (BMRN) vs. Incyte (INCY) Stock Comparison
Key Takeaways
- Incyte (INCY) exhibits stronger profitability with a 25% profit margin compared to BioMarin (BMRN)'s 10.8%, alongside lower debt-to-equity at 1.06% versus 10.6%.
- INCY has delivered approximately 60% one-year returns, outperforming BMRN's negative 15% amid recent share price weakness.
- Both stocks show year-to-date declines, with BMRN down around 10.5% and INCY off 4.2%, reflecting biotech sector volatility.
- INCY benefits from robust revenue growth, including 28% in Q4 2025 driven by Jakafi sales, while BMRN posted 17% quarterly growth.
- INCY's lower P/E ratio (price-to-earnings, 14.8) suggests better valuation relative to BMRN's 29.5.
Introduction
BioMarin Pharmaceutical (BMRN) and Incyte Corporation (INCY) represent distinct approaches within the biotechnology sector, with BMRN specializing in therapies for rare genetic disorders and INCY focusing on oncology and immunology treatments. This comparison analyzes their recent market performance, financial metrics, and growth drivers amid fluctuating biotech sentiment. Traders seeking momentum plays and long-term investors evaluating stability in pharmaceuticals will find value in understanding their relative positioning, sector exposures, and responses to recent clinical and earnings developments.
BMRN Overview and Recent Performance
BioMarin Pharmaceutical (BMRN) develops therapies for rare diseases, including VOXZOGO for achondroplasia and VIMIZIM for mucopolysaccharidosis (a lysosomal storage disorder). With a market capitalization of approximately $10.3 billion, the company reported trailing twelve-month (TTM) revenue of $3.22 billion and a profit margin of 10.8%. In recent market activity, shares have traded around $53, down over 10% year-to-date and 13.6% since the last earnings report, influenced by post-earnings weakness and pipeline updates like Voxzogo study discontinuations. Sentiment has been mixed, with analysts maintaining overweight ratings despite prolonged price declines, citing attractive valuations and forward P/E (price-to-earnings) of 10.5. Broader factors include board leadership changes and sector pressures on biotech stocks.
INCY Overview and Recent Performance
Incyte Corporation (INCY) is a biopharmaceutical firm centered on oncology and inflammation, led by flagship product Jakafi (ruxolitinib) for myelofibrosis and other conditions. Market cap stands at about $18.8 billion, with TTM revenue of $5.14 billion and a robust 25% profit margin. Shares hover near $95, reflecting a year-to-date dip of 4% but impressive 60% one-year gains. Recent weeks have seen positive momentum from strong Q4 2025 results with 28% revenue growth to $1.51 billion, driven by Jakafi and Opzelura sales, plus new data on povorcitinib and oncology collaborations. Upcoming Q1 earnings anticipation has bolstered sentiment, though shares dipped slightly post-quarter. Low beta (0.86) underscores relative stability versus broader biotech volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of the top 25 AI trading bots from over 351 available, chosen for their suitability in current market conditions across sectors like semiconductors, energy, and aerospace. These bots employ diverse strategies, including AI/ML signal agents, trend traders, and double agents with timeframes from 5 minutes to 60 minutes, trading thousands of tickers via stocks, ETFs, and leveraged instruments. Performance highlights include annualized returns up to 127% (e.g., GGLL bot), win rates of 50-75%, profit factors above 1.5, and profit-to-drawdown ratios exceeding 2 in many cases. Virtual and brokerage agents incorporate risk management like corridor take-profit/stop-loss. Explore these high-performing bots to align with your trading style and market outlook.
Head-to-Head Comparison
BioMarin (BMRN)'s niche in rare disease therapies offers high pricing power but narrower market exposure compared to Incyte's (INCY) diversified oncology portfolio anchored by blockbuster Jakafi. Growth drivers differ: BMRN relies on pipeline expansions like BMN 333 amid 17% quarterly revenue growth, while INCY leverages 28% surges from established drugs and new approvals. Recent momentum favors INCY with 60% annual gains versus BMRN's declines, though BMRN's lower beta (0.29) signals less volatility. Risk factors include BMRN's higher debt and clinical setbacks versus INCY's pristine balance sheet. Market sentiment tilts toward INCY ahead of earnings, positioning it for relative outperformance in biotech recovery trades.
Tickeron AI Verdict
Tickeron’s AI models currently favor Incyte (INCY) over BioMarin (BMRN), driven by superior trend consistency, higher profitability margins, explosive revenue growth, and positive catalysts like recent clinical data and earnings momentum. While BMRN offers undervaluation potential via forward metrics, INCY's stability and relative strength suggest greater probability of near-term upside in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and INCY is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMRN’s FA Score shows that 1 FA rating(s) are green whileINCY’s FA Score has 2 green FA rating(s).
- BMRN’s FA Score: 1 green, 4 red.
- INCY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMRN’s TA Score shows that 5 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s).
- BMRN’s TA Score: 5 bullish, 6 bearish.
- INCY’s TA Score: 5 bullish, 4 bearish.
Price Growth
BMRN (@Biotechnology) experienced а -1.44% price change this week, while INCY (@Biotechnology) price change was +6.01% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.
Reported Earning Dates
BMRN is expected to report earnings on Aug 04, 2026.
INCY is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Biotechnology (+0.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BMRN | INCY | BMRN / INCY | |
| Capitalization | 10.8B | 21.7B | 50% |
| EBITDA | 482M | 1.87B | 26% |
| Gain YTD | -5.856 | 9.882 | -59% |
| P/E Ratio | 40.25 | 15.33 | 263% |
| Revenue | 3.24B | 5.36B | 60% |
| Total Cash | 2.22B | 4.02B | 55% |
| Total Debt | 1.44B | 39.4M | 3,655% |
BMRN | INCY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 60 | |
SMR RATING 1..100 | 87 | 33 | |
PRICE GROWTH RATING 1..100 | 54 | 16 | |
P/E GROWTH RATING 1..100 | 12 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (72) in the Biotechnology industry is in the same range as BMRN (82). This means that INCY’s stock grew similarly to BMRN’s over the last 12 months.
INCY's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for BMRN (100). This means that INCY’s stock grew somewhat faster than BMRN’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is somewhat better than the same rating for BMRN (87). This means that INCY’s stock grew somewhat faster than BMRN’s over the last 12 months.
INCY's Price Growth Rating (16) in the Biotechnology industry is somewhat better than the same rating for BMRN (54). This means that INCY’s stock grew somewhat faster than BMRN’s over the last 12 months.
BMRN's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for INCY (100). This means that BMRN’s stock grew significantly faster than INCY’s over the last 12 months.
| BMRN | INCY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 69% | 3 days ago 49% |
| Stochastic ODDS (%) | 3 days ago 68% | 3 days ago 57% |
| Momentum ODDS (%) | 3 days ago 73% | 3 days ago 64% |
| MACD ODDS (%) | 3 days ago 71% | 3 days ago 69% |
| TrendWeek ODDS (%) | 3 days ago 65% | 3 days ago 64% |
| TrendMonth ODDS (%) | 3 days ago 55% | 3 days ago 62% |
| Advances ODDS (%) | 10 days ago 58% | 3 days ago 63% |
| Declines ODDS (%) | 4 days ago 62% | 13 days ago 59% |
| BollingerBands ODDS (%) | 3 days ago 75% | 3 days ago 62% |
| Aroon ODDS (%) | 5 days ago 57% | 5 days ago 56% |
Advertisement